Propulsid Revised Labeling Reserves Drug For Second-Line Use In GERD
Janssen's Propulsid (cisapride) should be reserved for second-line use, revised labeling recommends following additional reports of cardiac events and deaths associated with the drug for nocturnal heartburn caused by gastroesophageal reflux disease.
You may also be interested in...
Janssen will detail professional education campaign plans for conveying cardiac risks associated with the nighttime heartburn treatment Propulsid (cisapride) at the April 12 FDA advisory committee review of the product's safety.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011